NCT06851663RecruitingPhase 2/3
Trop2-targeted immunoPET Imaging of Solid Tumors
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 24 Feb 2025
- Start date
- 23 Dec 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- RenJi Hospital
- Diseases
- Prostate cancer, Head and neck cancer, Thyroid cancer, Bladder cancer, Endometrial cancer, Cervical cancer, Lung cancer, Liver and biliary tract cancer, Ovarian cancer
- NCT number
- NCT06851663
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 400
- From 23 Dec 2024 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe hepatic and renal insufficiency;
- Allergic to single-domain antibody radiopharmaceuticals.
Other
- Pregnancy；
Who the study is looking for
- Aged 18-75 year-old and of either sex
- Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;
- Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiao Tong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.